Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 142

1.

Efficacy of metrifonate in improving the psychiatric and behavioral disturbances of patients with Alzheimer's disease.

Cummings JL, Nadel A, Masterman D, Cyrus PA.

J Geriatr Psychiatry Neurol. 2001 Summer;14(2):101-8.

PMID:
11419566
2.

Metrifonate benefits cognitive, behavioral, and global function in patients with Alzheimer's disease.

Morris JC, Cyrus PA, Orazem J, Mas J, Bieber F, Ruzicka BB, Gulanski B.

Neurology. 1998 May;50(5):1222-30.

PMID:
9595967
3.
4.
5.

Metrifonate treatment of the cognitive deficits of Alzheimer's disease. Metrifonate Study Group.

Cummings JL, Cyrus PA, Bieber F, Mas J, Orazem J, Gulanski B.

Neurology. 1998 May;50(5):1214-21. Erratum in: Neurology 1998 Jul;51(1):332.

PMID:
9595966
9.

Metrifonate for Alzheimer's disease.

López-Arrieta JM, Schneider L.

Cochrane Database Syst Rev. 2006 Apr 19;(2):CD003155. Review.

PMID:
16625573
10.

Metrifonate treatment of AD: influence of APOE genotype.

Farlow MR, Cyrus PA, Nadel A, Lahiri DK, Brashear A, Gulanski B.

Neurology. 1999 Dec 10;53(9):2010-6.

PMID:
10599773
11.

Effects of metrifonate on cognitive decline in Alzheimer disease: a double-blind, placebo-controlled, 6-month study.

Becker RE, Colliver JA, Markwell SJ, Moriearty PL, Unni LK, Vicari S.

Alzheimer Dis Assoc Disord. 1998 Mar;12(1):54-7.

PMID:
9539412
12.
13.

Omega-3 supplementation in mild to moderate Alzheimer's disease: effects on neuropsychiatric symptoms.

Freund-Levi Y, Basun H, Cederholm T, Faxén-Irving G, Garlind A, Grut M, Vedin I, Palmblad J, Wahlund LO, Eriksdotter-Jönhagen M.

Int J Geriatr Psychiatry. 2008 Feb;23(2):161-9.

PMID:
17582225
14.

Efficacy of donepezil on behavioral symptoms in patients with moderate to severe Alzheimer's disease.

Gauthier S, Feldman H, Hecker J, Vellas B, Ames D, Subbiah P, Whalen E, Emir B; Donepezil MSAD Study Investigators Group.

Int Psychogeriatr. 2002 Dec;14(4):389-404.

PMID:
12670060
15.

The clinical trial protocol of the Metrifonate in Alzheimer's Trial (MALT).

McKeith IG.

Dement Geriatr Cogn Disord. 1998;9 Suppl 2:2-7.

PMID:
9718228
16.
17.

The impact of metrifonate therapy on caregivers of patients with Alzheimer's disease: results from the MALT clinical trial. Metrifonate in Alzheimer's Disease Trial.

Shikiar R, Shakespeare A, Sagnier PP, Wilkinson D, McKeith I, Dartigues JF, Dubois B.

J Am Geriatr Soc. 2000 Mar;48(3):268-74.

PMID:
10733052
18.

A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting.

Tariot PN, Cummings JL, Katz IR, Mintzer J, Perdomo CA, Schwam EM, Whalen E.

J Am Geriatr Soc. 2001 Dec;49(12):1590-9.

PMID:
11843990
19.

Galantamine treatment of problematic behavior in Alzheimer disease: post-hoc analysis of pooled data from three large trials.

Herrmann N, Rabheru K, Wang J, Binder C.

Am J Geriatr Psychiatry. 2005 Jun;13(6):527-34.

PMID:
15956273
20.

Double-blind, placebo-controlled study of metrifonate, an acetylcholinesterase inhibitor, for Alzheimer disease.

Becker RE, Colliver JA, Markwell SJ, Moriearty PL, Unni LK, Vicari S.

Alzheimer Dis Assoc Disord. 1996 Fall;10(3):124-31.

PMID:
8876775

Supplemental Content

Support Center